- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02875379
Clinical Comparison of Different Humidification Strategies During Noninvasive Ventilation With Helmet
Background. Non invasive positive pressure ventilation (NIV) is among first line treatments of acute respiratory failure. Several interfaces are available for non-invasive ventilation.Despite full face and oronasal masks are more frequently used, some evidence suggests that helmets may optimize patients' comfort and NIV tolerability.
During NIV, humidification strategies (heat and moisture exchangers HME or heated humidifiers HH) may significantly affect patient's comfort and work of breathing.
Despite physiological data suggested heated humidification as the best strategy during NIV with full face masks, no differences were found in a randomized controlled study assessing the effects of HME or HH on a pragmatic clinical outcome.
However, the higher dead space (i.e. 18 L/min) and rebreathing rate observed during helmet NIV make such results not applicable to this particular setting.
The investigators designed a randomized-crossover trial to assess the effect of four humidification strategies during helmet NIV on patients with acute respiratory failure, in terms of comfort, work of breathing and patient-ventilator interaction.
Methods. All awake, collaborative, hypoxemic patients requiring mechanical ventilation will be considered for the enrollment. Hypercapnic patients (i.e.PaCO2>45 mmHg) will be excluded.
Each enrolled patient will undergo helmet NIV with all the following humidification strategies in a random order. Each period will last 60 minutes.
- Passive humidification, double tube circuit.
- Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
- Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 37°C.
- Passive humidification with HME, Y-piece circuit.
Ventilatory settings (Draeger Evita xl or Evita infinity ventilators):
Pressure support ventilation; pressure support=20 cmH20; FiO2 titrated to obtain SpO2 between 92 and 98%; positive end-expiratory pressure=10 cmH2O; maximum inspiratory time 0.9 seconds; inspiratory flow trigger = 2 l/min; expiratory trigger: 30% of the maximum inspiratory flow; pressurization time=0,00 s.
Such settings will be kept unchanged during the whole study period. An oesophageal catheter will be placed and secured to measure oesophageal pressure (Pes) and gastric pressure (Pga) (Nutrivent, Italy): the reliability of the measured pressure will be confirmed with an airway occlusion test during NIV with oronasal mask. Work of breathing will be estimated with the pressure-time product (PTP) of the pleural pressure.
A pneumotachograph (KleisTek) will record flow, airway pressure, Pes and Pga on a dedicated laptop.
At the end of each cycle, the patient will be asked to rate his/her discomfort on a visual analog scale (VAS) modified for ICU patients. The level of dyspnea will be assessed with the Borg dyspnea scale.
The following parameters will be record at the end of each cycle:
Arterial pressure, heart rate, respiratory rate, SpO2, pH, PCO2, PaO2, SaO2. Airway and esophageal pressure signals will be reviewed offline to detect patient-ventilator asynchronies (ineffective efforts, double cycling, premature cycling, delayed cycling) and asynchrony index (number of asynchrony events divided by the total respiratory rate computed as the sum of the number of ventilator cycles (triggered or not) and of wasted efforts) will be computed. The trigger delay will be also measured. The pressurization and depressurization velocity will be assessed with the PTP airway index 300 and 500 (inspiratory and expiratory), as suggested by Ferrone and coworkers. The work of breathing (WOB) for each breath will be estimated by PTPes.
An hygrometer (Dimar SRL, Italy) will measure and record on a dedicated laptop Helmet temperature, relative and absolute humidity.
Primary endpoints: patient's comfort, work of breathing and asynchrony index.
Sample Sizing:
Given the physiological design of the study, the investigators did not make an a priori sample size and plan to enroll 24 patients.
Study Overview
Detailed Description
Background Non invasive positive pressure ventilation (NIV) is among first line treatments of acute respiratory failure. In patients with new-onset respiratory failure, NIV was showed to reduce the rate of complications and the length of ICU stay, as compared to invasive mechanical ventilation[1] Several interfaces are available for non-invasive ventilation: full face masks, oronasal masks, nasal prongs and helmets[2].
Despite full face and oronasal masks are more frequently used, some evidence suggests that helmets may optimize patients' comfort and NIV tolerability. The helmet allows patients' interaction, speech, feeding and does not limit cough. In addition, skin necrosis, gastric distension, or eye irritation are seldom observed during helmet NIV, while may be consequences of long-term treatments with face masks. [3] On the contrary, helmet NIV hampers tidal volume monitoring, is contraindicated in hypercapnic patients and requires specific ventilator settings[4]. Lastly, when compared to face masks, helmets may increase the work of breathing and worsen patient-ventilator interaction[5][6][7].
During NIV, humidification strategies (heat and moisture exchangers HME or heated humidifiers HH) may significantly affect patient's comfort and work of breathing [8][9].
Despite physiological data suggested heated humidification as the best strategy during NIV with full face masks[8][9], no differences were found in a randomized controlled study assessing the effects of HME or HH on a pragmatic clinical outcome[10].
However, the higher dead space (i.e. 18 L/min) and rebreathing rate observed during helmet NIV make such results not applicable to this particular setting.
One only study assessed the effects of a HH during helmet low-flow continuous positive airway pressure on comfort in healthy volunteers[11]. Indeed, patients suffering from acute respiratory failure may behave differently, especially in terms of minute ventilation and maximum inspiratory flow.
A recent bench study identified a better patient-ventilator interaction when helmet NIV was provided through a double tube circuit, as compared to the Y-piece system [12]. The investigators designed a randomized-crossover trial to assess the effect of four humidification strategies during helmet NIV on patients with acute respiratory failure, in terms of comfort, work of breathing and patient-ventilator interaction.
Methods Design: monocentric, randomized, cross-over trial. Each enrolled patient will undergo helmet NIV with all the following humidification strategies in a random order. Each period will last 60 minutes.
- Passive humidification, double tube circuit.
- Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
- Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 37°C.
- Passive humidification with HME, Y-piece circuit.
Ventilatory settings (Draeger Evita xl or Evita infinity ventilators):
Pressure support ventilation; pressure support=20 cmH20[4]; FiO2 titrated to obtain SpO2 between 92 and 98%; positive end-expiratory pressure=10 cmH2O[4]; maximum inspiratory time 0.9 seconds; inspiratory flow trigger = 2 l/min; expiratory trigger: 30% of the maximum inspiratory flow; pressurization time=0,00 s.
Such settings will be kept unchanged during the whole study period. An oesophageal catheter will be placed and secured to measure oesophageal pressure (Pes) and gastric pressure (Pga) (Nutrivent, Italy): the reliability of the measured pressure will be confirmed with an airway occlusion test during NIV with oronasal mask[13]. Work of breathing will be estimated with the pressure-time product (PTP) of the pleural pressure[13].
A pneumotachograph (KleisTek) will record flow, airway pressure, Pes and Pga on a dedicated laptop.
At the end of each cycle, the patient will be asked to rate his/her discomfort on a visual analog scale (VAS) modified for ICU patients. The level of dyspnea will be assessed with the Borg dyspnea scale[14].
The following parameters will be record at the end of each cycle:
Arterial pressure, heart rate, respiratory rate, SpO2, pH, PCO2, PaO2, SaO2. Airway and esophageal pressure signals will be reviewed offline to detect patient-ventilator asynchronies (ineffective efforts, double cycling, premature cycling, delayed cycling) and asynchrony index (number of asynchrony events divided by the total respiratory rate computed as the sum of the number of ventilator cycles (triggered or not) and of wasted efforts) will be computed[15]. The trigger delay will be also measured. The pressurization and depressurization velocity will be assessed with the PTP airway index 300 and 500 (inspiratory and expiratory), as suggested by Ferrone and coworkers[12]. The work of breathing (WOB) for each breath will be estimated by PTPes.
An hygrometer (Dimar SRL, Italy) will measure and record on a dedicated laptop Helmet temperature, relative and absolute humidity.
End point:
Primary endpoints: patient's comfort, work of breathing and asynchrony index.
Sample Sizing:
Given the physiological design of the study, the investigators did not make an a priori sample size and planned to enroll 24 patients.
Statistical analysis Qualitative data will be expressed as number of events (%) and continuous data as mean ± standard deviation or median [Interquartile range]. Comparisons concerning qualitative variables will be performed with the Mc-Namar test. Ordinal qualitative variables or non normal quantitative variables will be compared with the Friedman's Test, the wilcoxon sum of ranks test or the Mann-Whitney test, as appropriate. All analysis will be performed applying a bilateral hypothesis. P ≤ 0.05 will be considered significant. Statistical analysis will be performed with SPSS 20.0.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Rome, Italy, 00100
- General ICU, A. Gemelli hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Awake and collaborative patients
- Age>18 years
- Need for noninvasive mechanical ventilation
- Informed consent
Exclusion Criteria:
- Cardiopulmonary resuscitation
- Haemodynamic instability
- Coma
- Asma
- Hypercapnia (paCO2>45 mmHg)
- Recent gastric or abdominal surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HME
Passive humidification with heat and moisture exchanger, Y-piece circuit.
|
Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
|
Experimental: HH33
Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
|
Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
|
Experimental: HH37
Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
|
Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
|
Experimental: NoH
Passive humidification, double tube circuit
|
Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comfort assessed by visual analogic scale modified for ICU patients
Time Frame: At the end of each 1-hour ventilation period
|
Patient's comfort, assessed by visual analogic scale modified for ICU patients
|
At the end of each 1-hour ventilation period
|
Patient-ventilator asynchrony. Asynchrony index
Time Frame: At the end of each 1-hour ventilation period
|
Asynchrony index number of asynchrony events divided by the total respiratory rate computed as the sum of the number of ventilator cycles (triggered or not) and of wasted efforts.
Inspiratory trigger delay (time between the onset of patient's effort and ventilatory support).
Pressurization and depressurization efficacy.
|
At the end of each 1-hour ventilation period
|
Work of breathing. Oesophageal pressure time product
Time Frame: At the end of each 1-hour ventilation period
|
Pressure time product of the esophageal pressure (PTPes) and pressure time product of the transdiaphragmatic pressure (PTPdi)
|
At the end of each 1-hour ventilation period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PaO2
Time Frame: At the end of each 1-hour ventilation period
|
At the end of each 1-hour ventilation period
|
|
respiratory rate
Time Frame: At the end of each 1-hour ventilation period
|
At the end of each 1-hour ventilation period
|
|
Dyspnea
Time Frame: At the end of each 1-hour ventilation period
|
Borg dyspnea score
|
At the end of each 1-hour ventilation period
|
Helmet humidity
Time Frame: At the end of each 1-hour ventilation period
|
At the end of each 1-hour ventilation period
|
|
Helmet temperature
Time Frame: At the end of each 1-hour ventilation period
|
At the end of each 1-hour ventilation period
|
|
PaCO2
Time Frame: At the end of each 1-hour ventilation period
|
At the end of each 1-hour ventilation period
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11491/15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Failure
-
Poitiers University HospitalRecruitingAcute Respiratory Failure | Hypoxemic Respiratory FailureFrance
-
Catholic University of the Sacred HeartFisher and Paykel HealthcareCompletedWeaning Failure | Acute Respiratory FailureFrance, Greece, Italy, Spain
-
Hemovent GmbHMAXIS Medical, LLCActive, not recruitingRespiratory Failure | Cardiac Failure | Cardio-Respiratory FailureGermany
-
UPECLIN HC FM Botucatu UnespUnknownExtubation Failure | Acute Respiratory Failure Post ExtubationBrazil
-
Hospital Clinic of BarcelonaCompletedHypercapnic Respiratory Failure | Hypoxemic Respiratory FailureSpain
-
Efficacy Care R&D LtdMemorial Hermann Hospital; CRG Medical, Inc.UnknownShock | Shock, Septic | Respiratory Failure | Respiratory Distress Syndrome | Shock, Cardiogenic | Acute Cardiac Failure | Acute Respiratory Failure | Acute Kidney Failure | Multi Organ Failure | Respiratory Arrest | Acute Respiratory Failure With Hypoxia | Acute Respiratory Failure Requiring Reintubation | Acute... and other conditionsUnited States
-
University Hospital, AngersNot yet recruitingCardio-Respiratory FailureFrance
-
University Hospital, MotolCompletedRefractory Respiratory FailureCzechia
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedDevelopment of Modified Combined Apgar Scoring System for Evaluation of Infants in the Delivery RoomNeonatal Respiratory FailureTurkey
-
Siriraj HospitalRecruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory FailureThailand
Clinical Trials on Measurements
-
University Health Network, TorontoRecruitingRespiratory Insufficiency | Lung Injury | Mechanical Ventilation Complication | Diaphragm Injury | Abdominal Muscle StrainedCanada
-
Marmara UniversityRecruitingCerebral Palsy | Infant, Premature, Diseases | Preterm Birth ComplicationTurkey
-
Kahramanmaras Sutcu Imam UniversityCompletedCerebral Palsy | Infant, Premature, Diseases | Neurologic Disorder | Infant, Newborn, Disease | Infant Development | Development Delay | Infant, Very Low Birth Weight | Infant, Small for Gestational Age | Infant AsphyxiaTurkey
-
Pamukkale UniversityCompletedDiabetes Mellitus, Type 2 | Periodontitis | Coronary Heart Disease | Arterial StiffnessTurkey
-
Skulpt, Inc.National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Vanderbilt UniversityCompleted
-
University Hospital, Strasbourg, FranceRecruiting
-
Kahramanmaras Sutcu Imam UniversityCompletedInfant, Premature, Diseases | Sensory Processing Disorder | Sensory Disorder | Infant Development | Development Delay | Infant, Very Low Birth Weight | Infant Asphyxia | Motor DelayTurkey
-
University of Texas Southwestern Medical CenterCompleted